Oral tablet taken as soon as a day improves outcomes of sufferers with myelofibrosis
  • Reading time:3 min(s) read

Momelotinib, an oral tablet taken as soon as a day, considerably improved outcomes of sufferers handled for myelofibrosis (MF), a uncommon however deadly bone marrow most cancers, researchers reported June 7. Ruben Mesa, MD, FACP, govt director of the Mays Cancer Center, house to UT Health San Antonio MD Anderson Cancer Center, offered outcomes of the MOMENTUM part 3 randomized examine, which evaluated momelotinib towards a second remedy, danazol, in symptomatic and anemic MF sufferers beforehand handled with standard-of-care JAK inhibitor remedy.

Dr. Mesa, co-lead principal investigator of the examine, introduced the findings in Chicago on the Annual Meeting of the American Society of Clinical Oncology (ASCO). MOMENTUM enrolled 195 MF sufferers in 21 nations.


In myelofibrosis, scar tissue types within the bone marrow and hinders the physique’s capacity to provide wholesome blood cells. Anemia, a scarcity of pink blood cells to hold oxygen all through the physique, is noticed in just about all MF sufferers and negatively impacts survival, Dr. Mesa stated.

A 3rd of the sufferers have anemia up entrance, and most sufferers will develop it over the course of their illness. For sufferers with extreme anemia, survival is shortened to about two years. Even with gentle anemia, the median survival is 4.9 years. A drug to deal with anemia in these sufferers has been urgently wanted.”

Dr. Ruben Mesa, MD, FACP, govt director of the Mays Cancer Center

Without anemia, median survival with MF is nearer to eight years, he stated.

Myelofibrosis options irregular signaling of JAK proteins and extreme activation of one other protein, ACVR1. Pioneering MF medication developed during the last decade, akin to ruxolitinib, inhibit the dangerous JAK signaling, whereas momelotinib is the primary drug that inhibits each JAK and ACVR1, Dr. Mesa stated.

“It has JAK1, JAK2 and ACVR1 inhibitors in one drug and addresses chronic inflammation due to the hyperactivation of ACVR1 as a consequence of the disease,” Dr. Mesa stated.


Of the enrolled individuals, 130 acquired momelotinib and 65 danazol. Participants didn’t know till after 24 weeks which drug they acquired, and people within the danazol group had been allowed to cross over to momelotinib at the moment.

In the momelotinib group:

  • All prespecified major and key secondary endpoints had been met.
  • Significant enhancements in signs, spleen measurement and anemia measures had been noticed.
  • Favorable security and a development towards improved general survival had been documented.
  • Participants required fewer transfusions to interchange pink blood cells and evidenced higher oxygen-carrying hemoglobin ranges.

“The results were compelling,” Dr. Mesa stated. “The examine enrolled individuals fully in the course of the COVID timeframe, which was exceptional. Momelotinib met all major and secondary endpoints and inside the brief span of six months, there was a development towards general survival profit, which can also be exceptional.

“Findings support the future use of momelotinib as an effective treatment in MF patients, especially in those with anemia,” Dr. Mesa concluded.

The MOMENTUM examine was sponsored by Sierra Oncology of San Mateo, Calif.

If you are interested in working in a distraction free environment, visit our site Blissful Noises where we provide various sounds and features to help you focus or relax.